A phase I/II study of intracerebroventricular administration of GC1123 for the treatment of neurocognitive decline associated with Hunter syndrome

Trial Profile

A phase I/II study of intracerebroventricular administration of GC1123 for the treatment of neurocognitive decline associated with Hunter syndrome

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Idursulfase (Primary)
  • Indications Mucopolysaccharidosis II
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Nov 2016 New trial record
    • 25 Oct 2016 According to a Green Cross Corporation media release, the National Center for Child Health and Development (NCCHD) in Japan has initiated this study and the principal investigator is Torayuki Okuyama M.D., Director of Clinical Laboratory Medicine at NCCHD.
    • 25 Oct 2016 According to a Green Cross Corporation media release, first patient has begun treatment in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top